Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Knight Therapeutics Inc T.GUD

Alternate Symbol(s):  KHTRF

Knight Therapeutics Inc. is a specialty pharmaceutical company. The Company’s principal business activity is developing, acquiring, in-licensing, out-licensing, manufacturing, marketing and distributing pharmaceutical products in Canada, Latin America and select international markets. It finances other life sciences companies and secures product distribution rights for Canada and select international markets. The Company invests in life sciences venture capital funds whereby the Company may receive preferential access to healthcare products for Canada and select international markets. It develops pharmaceutical products, including those to treat neglected tropical and rare pediatric diseases. The portfolio consists of pharmaceutical products with molecules and includes both in-licensed products such as Lenvima, Cresemba, Halaven, Trelstar, Akynzeo, Ambisome, Minjuvi, Imvexxy as well as products owned by Knight such as Exelon and Impavido.


TSX:GUD - Post by User

Bullboard Posts
Post by bthoughtson May 17, 2015 10:04pm
414 Views
Post# 23737890

Value

Value

Hey folks,

Based on latest quarterly information from March 2015:

https://www.gud-knight.com/images/financial/Knight-MDA-2015-Q1-EN.pdf

Here are the straight facts on Knight Theraputics current valuation as of March 2015:

Basic Earings Per Share

Q1 2014 - (0.01)
Q2 2014 - 0.006
Q3 2014 - 0.007
Q4 2014 - 1.58
Q1 2015 - 0.15

Based on the above information, average EPS is 0.34

Based on current $7.05 share price this means a PE ratio of 20.73

Book value is $5.64
from $525,423,931 (total assets) divide by 93,092,700 (common shares)

--

My humble opinon is that this is a good speculative growth stock.

Read the link below to get a better idea of Knight's strategy and business model:

https://www.gud-knight.com/images/presentation/Knight_Bloom_Burton_Conference-May_4_2015.pdf

This is deifnitely long term at least 4 to 5 years for us to see results from its current investments, secured loans and revenue from pipeline products.

With the previous success story of Paladin, further with the hype of the healthcare industry and stock performance like CXR, investors have become delusioned and impatient expecting stocks like GUD to do the same. Honestly though look at the net income of the previous two quarters, brilliant play with selling the priorty voucher, and investment return from CRH. This goes to show that management knows what they are doing.

I think the market just has an unrealistic high expectation for this stock to jump to a ridiculous stock price like $150. It took 20 years for Paladin to be an overnight $150 stock.

With patience and in good time I think as a shareholder you will be greatly rewarded with this one.

Bullboard Posts